Sumen Cenk 4
4 · MAXCYTE, INC. · Filed Mar 21, 2023
Insider Transaction Report
Form 4
MAXCYTE, INC.MXCT
Sumen Cenk
Chief Scientific Officer
Transactions
- Award
Employee Stock Option (right to buy)
2023-03-20+120,000→ 120,000 totalExercise: $4.19Exp: 2033-03-19→ Common Stock (120,000 underlying) - Award
Employee Stock Option (right to buy)
2022-04-11+500,000→ 500,000 totalExercise: $5.70Exp: 2032-04-10→ Common Stock (500,000 underlying)
Footnotes (3)
- [F1]As announced in a press release by the issuer on April 15, 2022, on April 11, 2022 the Issuer awarded a stock option to the Reporting Person as a material inducement to his employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option was granted under the Issuer's 2021 Inducement Plan. However, due to an administrative oversight, the stock option grant was not previously reported on a Form 4 as required and is being reported on this report.
- [F2]25% of the shares underlying this option vest on April 11, 2023 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date.
- [F3]25% of the shares underlying this option vest on March 20, 2024 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date.